TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07712562: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes

Sponsor: Dren Bio · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,241,680

Rescue Site Savings

+$818,380

Unlock Full NCT07712562 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07712562 Rescue Dossier →